LGND vs. NRIX, PRAX, TVTX, ARCT, CMPS, IONS, RGEN, HALO, EXEL, and MDGL
Should you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include Nurix Therapeutics (NRIX), Praxis Precision Medicines (PRAX), Travere Therapeutics (TVTX), Arcturus Therapeutics (ARCT), COMPASS Pathways (CMPS), Ionis Pharmaceuticals (IONS), Repligen (RGEN), Halozyme Therapeutics (HALO), Exelixis (EXEL), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "medical" sector.
Ligand Pharmaceuticals (NASDAQ:LGND) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, community ranking, analyst recommendations, valuation and risk.
Ligand Pharmaceuticals received 476 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. However, 74.68% of users gave Nurix Therapeutics an outperform vote while only 70.12% of users gave Ligand Pharmaceuticals an outperform vote.
Ligand Pharmaceuticals has a net margin of 79.30% compared to Nurix Therapeutics' net margin of -264.84%. Ligand Pharmaceuticals' return on equity of 8.52% beat Nurix Therapeutics' return on equity.
Ligand Pharmaceuticals currently has a consensus price target of $126.33, indicating a potential upside of 17.91%. Nurix Therapeutics has a consensus price target of $25.82, indicating a potential upside of 17.68%. Given Ligand Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Ligand Pharmaceuticals is more favorable than Nurix Therapeutics.
In the previous week, Ligand Pharmaceuticals had 4 more articles in the media than Nurix Therapeutics. MarketBeat recorded 8 mentions for Ligand Pharmaceuticals and 4 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.92 beat Ligand Pharmaceuticals' score of 0.75 indicating that Nurix Therapeutics is being referred to more favorably in the news media.
Ligand Pharmaceuticals has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500.
91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 5.9% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 7.2% of Nurix Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Ligand Pharmaceuticals has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Ligand Pharmaceuticals beats Nurix Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Ligand Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ligand Pharmaceuticals Competitors List
Related Companies and Tools
